HIGHLIGHTS
- who: Kiyoshi Seki from the approved in Japan have published the research: Lifecycle management of orphan drugs approved in Japan, in the Journal: (JOURNAL) of September/17,/2019
- what: The authors aim to clarify the OD LCM activity in Japan through investigations of additional indications and marketing exclusivity using the patent extension and re-examination system. The authors here discuss the types of patented inventions. Summary of LCM by adding indications and registering patent extensions Regarding limitations of LCM by adding indications and registering patent extensions, this study showed that 26 ODs (13% of the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.